Experts Established Cardiac Imaging Standards
Clinicians have identified SPECT/CT imaging as the primary noninvasive method for diagnosing transthyretin cardiac amyloidosis.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Do you trust established medical diagnostic procedures more than emerging experimental testing methods?
Medical experts have confirmed SPECT/CT imaging as the standard diagnostic tool for detecting transthyretin cardiac amyloidosis. This noninvasive approach improves accuracy by distinguishing myocardial uptake from surrounding blood-pool activity.
Why it matters
The rise of effective disease-modifying therapies makes early, precise identification of cardiac amyloidosis essential for patient outcomes. Bone-avid tracers allow clinicians to avoid invasive procedures while diagnosing these specific protein deposits.
Cardiac amyloidosis occurs in 13% of heart failure cohorts and 10% of aortic stenosis patients. Imaging using the PET tracer evuzamitide currently requires a delay of 4 to 5 hours to ensure adequate clearance of blood-pool activity before assessment.
The players
SPECT/CT
This advanced imaging technology allows medical professionals to differentiate between myocardial uptake and surrounding signals.
The details
SPECT/CT imaging utilizes bone-avid tracers like Technetium-99m PYP, DPD, and HMDP to visualize misfolded protein deposits within the myocardium. While research into PET tracers like iodine-124 evuzamitide continues, these tools are not yet available for standard clinical diagnosis.
Timeline
Experts discussed cardiac amyloidosis imaging standards during a webinar on September 22, 2026.
The Big Picture
The identification of these imaging standards follows a pattern set by the development of disease-modifying therapies for cardiac amyloidosis. As new drugs reach the market, the shift toward standardized, noninvasive detection becomes vital for identifying candidates for treatment.
Patients experiencing heart failure or aortic stenosis can expect more reliable, noninvasive diagnostic pathways to identify amyloidosis. These standards reduce the necessity for invasive testing while ensuring that clinicians can more accurately monitor disease progression.
The takeaway
Reliable noninvasive imaging is currently the most effective way to detect protein deposits in the heart. Clinicians are shifting toward standardized SPECT/CT protocols while continuing to evaluate future PET tracers for better quantitative accuracy.
Further reading
For more information on the latest diagnostics, visit the Heart Disease section.
Source note: This article includes information reported by AuntMinnieEurope.
Live Poll
Do you trust established medical diagnostic procedures more than emerging experimental testing methods?
